Taiho Ventures

Taiho Ventures, LLC serves as the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharmaceutical company specializing in oncology, allergy, immunology, and urology. The firm invests in early-stage biotech ventures worldwide, focusing on innovative first-in-class drug discovery, unique platform technologies, and spin-outs, particularly in preclinical oncology companies and modalities spanning biologics and small molecules. With $400 million under management, Taiho Ventures supports companies that align with Taiho Pharmaceutical's growth strategy, including option-type investments alongside traditional equity deals. Established in 2016, Taiho Ventures was created to accelerate open innovation by scouting promising global startups and channeling cutting-edge science back to its parent company. The firm expanded its investment pool from $300 million to $400 million in 2024, underscoring its commitment to high-quality biotech investments amid a robust portfolio of over 25 companies. This growth reflects Taiho Pharmaceutical's dedication to sustainable delivery of new technologies and treatments, building on its reputation as a leader in oncology drug development. Taiho Ventures boasts a diverse portfolio featuring standout investments such as Arcus Biosciences, Cullinan Pearl (now Cullinan Oncology), Dren Bio, Orna Therapeutics, Werewolf Therapeutics, EpiBiologics, Anavo Therapeutics, Harpoon Therapeutics, and PACT Pharma. These companies primarily advance cancer immunotherapies, biopharma therapeutics, and novel platforms, with the firm participating in seed, Series A, and Series B rounds. Several portfolio firms have achieved exits through IPOs or M&As, validating the firm's deal-sourcing prowess. Led by President and CEO Sakae Asanuma, who heads a compact five-person team in California, Taiho Ventures draws on deep expertise in biotech investing. Asanuma has backed over 60 companies, many resulting in successful IPOs or acquisitions, and has executed key collaborations under prior roles at Taiho Ventures and Astellas Venture Management. The team's strategic focus on build-to-buy and spin-out deals enhances Taiho Pharmaceutical's R&D pipeline.